Trial Profile
A Phase III Randomized Trial With NEOadjuvant Chemotherapy (TAC) With or Without ZOledronic Acid for Patients With HER2- Negative Large Resectable or Locally Advanced Breast Cancer(NEO-ZOTAC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Pegfilgrastim
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- Acronyms NEO-ZOTAC
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
- 15 Jul 2014 Status changed to completed as reported by ClinicalTrials.gov record.
- 05 Jun 2013 Primary endpoint 'Complete-pathological-response-rate' has not been met.